Soligenix Launches $8M Offering to Dodge Nasdaq Delisting

TL;DR

**SNGX is scrambling to raise $8M to avoid Nasdaq delisting, making this a high-risk, speculative play on their pipeline's future success.**

AI Summary

Soligenix, Inc. (SNGX) is conducting an offering of up to $8.0 million in common stock and warrants to address its non-compliance with Nasdaq's minimum stockholders' equity requirement. As of June 30, 2025, the company reported stockholders' equity of $1,828,951, falling below the Nasdaq Capital Market's $2,500,000 threshold. The offering includes up to 2,909,090 shares of common stock, or pre-funded warrants, along with common warrants to purchase an equal number of shares, with an assumed public offering price of $2.75 per share. The company estimates it will regain compliance if it receives net proceeds of at least $3.4 million from this offering. Soligenix is a late-stage biopharmaceutical company with two segments: Specialized BioTherapeutics, featuring HyBryte for CTCL with Phase 3 FLASH2 results anticipated in H2 2026, and Public Health Solutions, including RiVax and ThermoVax, primarily supported by government grants. The offering is expected to close by October 28, 2025.

Why It Matters

This offering is critical for Soligenix to maintain its Nasdaq listing, directly impacting investor confidence and the liquidity of SNGX shares. Failure to regain compliance by the September 29, 2025 deadline, or the extended 180-day period, could lead to delisting, severely limiting the ability of investors to trade their securities and hindering future capital raises. For employees and customers, continued listing provides stability and validates the company's ongoing drug development efforts, particularly for HyBryte in CTCL, which faces a competitive landscape with other emerging therapies for rare dermatological conditions. The broader market will watch to see if this capital infusion enables SNGX to advance its pipeline, especially with the anticipated FLASH2 study results in late 2026.

Risk Assessment

Risk Level: high — The company explicitly states it received a Nasdaq notice on August 15, 2025, for non-compliance with the $2,500,000 minimum stockholders' equity requirement, reporting only $1,828,951 as of June 30, 2025. Failure to raise at least $3.4 million in net proceeds from this offering, or to have its compliance plan accepted, could lead to delisting. Furthermore, the offering has no minimum aggregate amount of proceeds, meaning the company may not raise sufficient funds to achieve its business goals, leaving investors exposed.

Analyst Insight

Investors should approach SNGX with extreme caution, recognizing the immediate delisting risk. Consider this a highly speculative investment, contingent on the company successfully raising the necessary capital and advancing its clinical pipeline, particularly the HyBryte FLASH2 study. Monitor the offering's progress and the company's Nasdaq compliance status closely before making any investment decisions.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $8.0 million — Maximum gross proceeds from offering (Targeted capital raise to address Nasdaq compliance and fund operations)
• $1,828,951 — Stockholders' equity as of June 30, 2025 (Below Nasdaq's minimum requirement, triggering the non-compliance notice)
• $2,500,000 — Nasdaq minimum stockholders' equity requirement (Threshold SNGX must meet to maintain listing)
• $3.4 million — Estimated net proceeds needed for Nasdaq compliance (Minimum amount SNGX believes it needs to raise from this offering)
• 2,909,090 — Maximum shares of common stock/pre-funded warrants offered (Number of securities being sold in the offering)
• $2.75 — Assumed public offering price per share (Last reported sale price on Nasdaq on September 15, 2025)
• 6.5% — Placement Agent cash commission (Fee paid to A.G.P. on aggregate proceeds, with exceptions)
• September 29, 2025 — Deadline to submit Nasdaq compliance plan (Initial deadline given by Nasdaq after the August 15, 2025 notice)
• October 28, 2025 — Offering termination date (Latest date for the offering of common stock, pre-funded warrants, or common warrants)
• Second half of 2026 — Anticipated top-line results for FLASH2 study (Key milestone for HyBryte (SGX301) development)

Key Players & Entities

• SOLIGENIX, INC. (company) — Registrant and biopharmaceutical company
• Nasdaq Capital Market (regulator) — Stock exchange where SNGX is listed
• A.G.P./Alliance Global Partners (company) — Sole placement agent for the offering
• Christopher J. Schaber, Ph.D. (person) — President and Chief Executive Officer of Soligenix, Inc.
• Driscoll R. Ugarte, Esq. (person) — Legal counsel from Duane Morris LLP
• Duane Morris LLP (company) — Legal counsel for Soligenix, Inc.
• Sullivan & Worcester LLP (company) — Legal counsel for Soligenix, Inc.
• HyBryte (SGX301) (company) — Lead product candidate for Cutaneous T-cell Lymphoma
• RiVax (company) — Ricin toxin vaccine candidate
• National Institute of Allergy and Infectious Diseases (NIAID) (regulator) — Government grant provider

FAQ

Risk Factors

• Nasdaq Non-Compliance [high — financial]: Soligenix, Inc. is currently not in compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000, reporting only $1,828,951 as of June 30, 2025. This offering aims to raise at least $3.4 million in net proceeds to regain compliance, with a deadline to submit a compliance plan by September 29, 2025.
• Offering Dilution and Liquidity [medium — financial]: The offering of up to 2,909,090 shares at $2.75 per share, along with warrants, will dilute existing shareholders. There is no established trading market for the pre-funded warrants or common warrants, limiting their liquidity.
• Clinical Trial and Development Risks [high — operational]: The company's success hinges on the development of its biopharmaceutical products, particularly HyBryte for CTCL. Phase 3 FLASH2 study results are anticipated in H2 2026, and any delays or negative outcomes pose significant risks to future revenue and market position.
• Dependence on Government Grants [medium — financial]: The Public Health Solutions segment, including RiVax and ThermoVax, is primarily supported by government grants. Changes in government funding priorities or contract awards could materially impact this segment's financial contribution.
• Regulatory Approval Pathway [high — regulatory]: As a biopharmaceutical company, Soligenix faces extensive regulatory hurdles for its product candidates. Delays or failures in obtaining FDA or other regulatory approvals for HyBryte, RiVax, or ThermoVax would severely impact commercialization prospects.
• Limited Operating History and Profitability [high — financial]: The company has a limited operating history and has not demonstrated consistent profitability. The current offering is crucial for continued operations and Nasdaq compliance, highlighting financial vulnerability.
• Future Capital Requirements [high — financial]: Even with the current offering, Soligenix may require substantial additional capital to fund ongoing research, clinical trials, and potential commercialization of its products. Failure to secure future funding could jeopardize its business.
• Lock-up Agreement Restrictions [low — financial]: The company has agreed to a 30-day lock-up period post-offering, restricting the issuance of new shares. Additionally, a one-year restriction on variable rate transactions, excluding 'at the market' offerings, limits financial flexibility.

Industry Context

Soligenix operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry. The company focuses on developing treatments for rare diseases and public health threats. Key competitors include established pharmaceutical giants and emerging biotech firms, all vying for market share and regulatory approval. The industry is characterized by long development cycles, high R&D costs, and significant regulatory oversight from bodies like the FDA.

Regulatory Implications

Soligenix faces substantial regulatory risks inherent in drug development. Obtaining approval for its lead candidates, such as HyBryte for CTCL, requires rigorous clinical trials and adherence to strict FDA guidelines. Failure to meet these standards or delays in the approval process can significantly impede market entry and commercial success. Furthermore, the company's Nasdaq listing is contingent on meeting financial compliance requirements, adding another layer of regulatory pressure.

What Investors Should Do

1. Monitor Nasdaq Compliance Status
2. Evaluate Clinical Trial Progress
3. Assess Funding Needs and Future Capital Raises
4. Understand Warrant Terms and Dilution

Key Dates

• 2025-09-29: Deadline to submit Nasdaq compliance plan — Critical date for the company to demonstrate its plan to regain Nasdaq listing compliance.
• 2025-10-28: Offering termination date — Latest date for the completion of the current capital raise, essential for addressing Nasdaq non-compliance and funding operations.
• 2026-06-30: Anticipated top-line results for FLASH2 study — Key milestone for HyBryte (SGX301) development, which could significantly impact the company's valuation and future prospects.

Glossary

Pre-funded warrants

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price, often used in offerings to allow investors to avoid immediate dilution or to facilitate a more immediate start to their investment. (Offered in this S-1 filing as an alternative to common stock, potentially impacting the immediate share count and dilution.)

Common warrants

A security that gives the holder the right, but not the obligation, to buy a company's common stock at a specified price (the exercise price) before a certain expiration date. (Included in the offering, these warrants represent potential future dilution and provide additional capital to the company upon exercise.)

Stockholders' equity

The value of a company's assets minus its liabilities, representing the owners' stake in the company. (Soligenix's current stockholders' equity of $1,828,951 is below the Nasdaq minimum of $2,500,000, triggering the need for this offering.)

At Market Issuance Sales Agreement

An agreement allowing a company to sell its shares of common stock into the open market at prevailing market prices, typically used for ongoing capital raising efforts. (Mentioned as an exception to the lock-up agreement, indicating a potential avenue for future capital raises.)

CTCL

Cutaneous T-cell Lymphoma, a type of non-Hodgkin lymphoma that affects the skin. (HyBryte, a key product candidate for Soligenix, is being developed for the treatment of CTCL.)

Reverse stock split

A corporate action where a company reduces the number of outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Soligenix effectuated a one-for-sixteen reverse stock split on June 5, 2024, which is reflected in the share counts presented in the filing.)

Year-Over-Year Comparison

Information comparing key metrics to a previous filing is not available in the provided text. The S-1 filing focuses on the current offering and the company's status as of the filing date, including its Nasdaq non-compliance and development pipeline.

Key Financial Figures

• $8.0 million — Common Warrants We are offering up to $8.0 million of shares of common stock together with
• $2.75 — have assumed a public offering price of $2.75 per share, the last reported sale price
• $0.001 — mmon stock and has an exercise price of $0.001 per share. Each pre-funded warrant is b
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
• $1,828,951 — 25, we reported stockholders' equity of $1,828,951, which is below the Stockholders' Equit
• $1,439,300 — d total gross proceeds of approximately $1,439,300. Additionally, as of the date of the No
• $35 m — value of listed securities of at least $35 million, or net income of $500,000 from c
• $500,000 — at least $35 million, or net income of $500,000 from continuing operations in the most
• $2.5 million — hat we will have more than the required $2.5 million in shareholders' equity as of the closi
• $3.4 million — ded we receive net proceeds of at least $3.4 million in this offering. There can be no assur
• $250 million — on stock held by non-affiliates exceeds $250 million as of the prior June 30, or (2) our ann
• $100 million — 30, or (2) our annual revenues exceeded $100 million during such completed fiscal year and t
• $700 million — on stock held by non-affiliates exceeds $700 million as of the prior June 30. Our Product
• $0 — d to the public in this offering, minus $0.001, and the exercise price of each pre
• $7.3 m — rom this offering will be approximately $7.3 million, at an assumed public offering pr

Filing Documents

• sngx-20250630xs1.htm (S-1) — 4988KB
• sngx-20250630xex1d1.htm (EX-1.1) — 72KB
• sngx-20250630xex4d2.htm (EX-4.2) — 122KB
• sngx-20250630xex4d3.htm (EX-4.3) — 120KB
• sngx-20250630xex4d4.htm (EX-4.4) — 270KB
• sngx-20250630xex5d1.htm (EX-5.1) — 27KB
• sngx-20250630xex21d1.htm (EX-21.1) — 9KB
• sngx-20250630xex23d1.htm (EX-23.1) — 4KB
• sngx-20250630xexfees.htm (EX-FILING FEES) — 41KB
• sngx-20250630xs1004.jpg (GRAPHIC) — 5KB
• sngx-20250630xs1012.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1013.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1014.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1015.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1019.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1020.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1022.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1023.jpg (GRAPHIC) — 1KB
• sngx-20250630xs1031.gif (GRAPHIC) — 2KB
• sngx-20250630xex5d1001.jpg (GRAPHIC) — 6KB
• sngx-20250630xex5d1002.jpg (GRAPHIC) — 5KB
• 0001104659-25-091717.txt ( ) — 20902KB
• sngx-20250630.xsd (EX-101.SCH) — 79KB
• sngx-20250630_cal.xml (EX-101.CAL) — 58KB
• sngx-20250630_def.xml (EX-101.DEF) — 465KB
• sngx-20250630_lab.xml (EX-101.LAB) — 576KB
• sngx-20250630_pre.xml (EX-101.PRE) — 711KB
• sngx-20250630xs1_htm.xml (XML) — 3591KB
• sngx-20250630xexfees_htm.xml (XML) — 13KB

RISK FACTORS

RISK FACTORS 8 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA AND MARKET INFORMATION 40

USE OF PROCEEDS

USE OF PROCEEDS 42 DIVIDEND POLICY 43 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 43 CAPITALIZATION 45

DILUTION

DILUTION 47 MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 49

BUSINESS

BUSINESS 58 MANAGEMENT 85

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 91 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 96

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS

SECURITY OWNERSHIP OF MANAGEMENT AND OTHER BENEFICIAL OWNERS 97

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 98

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 102 PLAN OF DISTRIBUTION 105 LEGAL MATTERS 107 EXPERTS 107 WHERE YOU CAN FIND MORE INFORMATION 107 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F- 1 Neither we nor the Placement Agent have authorized anyone to give any information or to make any representations other than those contained in this prospectus. You must not rely on any information or representations not contained in this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. i Table of Contents PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should carefully read this entire prospectus before making an investment decision, including the information presented under the headings "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements and Industry Data and Market Information" in this prospectus and the historical financial statements and the notes thereto included elsewhere in this prospectus. You should pay special attention to the information contained under the caption titled "Risk Factors" in this prospectus, before deciding to buy our securities. In this prospectus, the terms " Soligenix, " " Soligenix, Inc., " the " Company, " "we, " " our, " " ours " and " us " refer to Soligenix, Inc. and its subsidiaries. Overview We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions. Our Specialized BioTherapeutics business segment is developing and moving toward potent

Use of proceeds

Use of proceeds We estimate that the net proceeds from this offering will be approximately $7.3 million, at an assumed public offering price of $2.75 per share (assuming a public offering price equal to the last sale price of our common stock as reported by The Nasdaq Capital Market on September 15, 2025, which was $2.75 per share), after deducting the Placement Agent fee and estimated offering expenses payable by us. We intend to use the net proceeds from the sale of the securities offered by us pursuant to this prospectus to fund our research and development and commercialization activities, and for general corporate and working capital purposes, which may include, among other things, working capital, product development and/or commercialization, acquisitions, capital expenditures, repayment 4 Table of Contents of debt and other business opportunities. See the section titled "Use of Proceeds" on page 42 of this prospectus. Amendment to certain outstanding warrants In connection with the offering pursuant to this prospectus, we may amend the terms of up to 1,467,581 issued and outstanding warrants to reduce the exercise price of such warrants to: (i) equal the exercise price of the common warrants sold in this offering; and (ii) extend the term during which the such warrants could remain exercisable to the term of the common warrants sold in this offering.

Risk Factors

Risk Factors See "Risk Factors" and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully consider before deciding whether to invest in our securities. Lock-up We have agreed, subject to certain exceptions and without the approval of the Placement Agent and purchasers of our securities in this offering, not to (1) issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of common stock (or securities convertible into or exercisable for common stock) or file any registration statement, including any amendments or supplements for a period of 30 days following the closing of the offering of the shares and (2) enter into a variable rate transaction for a period of one year following the closing of this offering, other than the issuance of shares of our common stock in an "at the market" offering, including pursuant to that certain At Market Issuance Sales Agreement by and among the Company and the Placement Agent dated August 16, 2024, following 30 days from the closing of this offering. See "Plan of Distribution" for more information. The Nasdaq Capital Market listing symbol "SNGX." There is no established trading market for the pre-funded warrants or the common warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the pre-funded warrants or the common warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the pre-funded warrants and common warrants will be limited. The number of shares of common stock to be outstanding after this offering is based on 4,285,570 shares of common stock outstanding on September 15, 2025, does not give effect to the shares of common stock issuable upon exercise of the pre-funded warrants and common warrants issued in this offering and excludes: 1,467,581 shares of common stock issuable upon the exercise of outst

View Full Filing

View this S-1 filing on SEC EDGAR